Discovery of Begacestat, a Notch-1-Sparing γ-Secretase Inhibitor for the Treatment of Alzheimer’s Disease
Scott C. Mayer, J. Steven Jacobsen, Thomas A. Comery(Princeton University), Magid Abou‐Gharbia, Yun Hu(Princeton University), Derek C. Cole, Menelas N. Pangalos(AstraZeneca (United Kingdom)), Kenneth Kremer, Cathleen Gonzales, David Riddell(Eli Lilly (United States)), John W. Ellingboe(Pearl River Community College), George Diamantidis, Joseph R. Stock, Joseph Zeldis, Melissa Lin, Madelene Antane, R. L. Magolda, Mei Jin, Erik Wagner(Princeton University), Rocco J. Galante, Kristi Fan, Uday Jain, June Sonnenberg‐Reines, Kevin R. Woller, Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter H. Reinhart(University of Massachusetts Amherst), Minsheng Zhang, Molly Hoke, William Moore, Robert Martone(Princeton University), Anthony F. Kreft, Shaiu-Ching Sun, Donna M. Huryn, Dennis Kubrak, Ting Wang(Shenyang Pharmaceutical University), Zheng Xu(First Teaching Hospital of Tianjin University of Traditional Chinese Medicine), Hua Zhou, Peimin Lu, Michael Chlenov, Alex Porte, Suzan Aschmies(Princeton University), Lynn Resnick, Douglas M. Ho, Aram Oganesian(Plex Pharmaceuticals (United States)), Boyd L. Harrison, Margaret M. Zaleska
Cited by 111
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302